Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. (LFST) Form 144 notifies the market of a proposed sale of 35,938 shares of common stock through Morgan Stanley & Co. LLC, with an aggregate market value of $194,424.58. The filing states the securities will be sold approximately on 08/18/2025 on NASDAQ and shows 388,936,394 shares outstanding. The shares were originally acquired 06/10/2021 in a pre-IPO transaction (206,219 shares acquired) from LifeStance Health Group Inc. No sales by the seller are reported in the past three months.
LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 3,759 shares of Common Stock through Morgan Stanley & Co. LLC with an aggregate market value of $20,336.19. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025.
The shares were originally acquired 06/10/2021 in pre-IPO transactions from LifeStance Health Group Inc.; the filer reported acquiring 21,572 shares on that date. The notice states there were no securities sold by the account in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Kenneth A. Burdick, a director of LifeStance Health Group, Inc. (LFST), reported multiple open-market purchases of common stock on August 8 and August 11, 2025. The filings show acquisitions totaling 67,670 shares at prices between $4.30 and $4.54. After these transactions his reported direct beneficial ownership rose to 3,436,571 shares, and he also holds 46,511 shares indirectly through Burdick Family LLC.